Company profile for NRG Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will in...
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Cambridge, Cambridgeshire GB
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3196724/0/en/NRG-Therapeutics-Announces-Further-Expansion-with-the-Appointment-of-Paul-Thompson-as-Chief-Development-Officer.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/10/23/3171716/0/en/NRG-Therapeutics-Announces-Senior-Appointments-as-it-Advances-NRG5051-Towards-First-in-Human-Clinical-Studies.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/09/08/3145831/0/en/NRG-Therapeutics-Announces-Oversubscribed-50m-67m-Series-B-Financing-to-Deliver-Clinical-Data-in-Parkinson-s-and-Proof-of-Concept-in-ALS-MND.html

GLOBENEWSWIRE
08 Sep 2025

https://www.globenewswire.com/news-release/2024/10/31/2972343/0/en/NRG-Therapeutics-Selects-First-Development-Candidate-NRG5051-and-Secures-Grant-from-The-Michael-J-Fox-Foundation-for-Development-of-mPTP-Inhibitors-to-Treat-Neurodegenerative-Disea.html

GLOBENEWSWIRE
31 Oct 2024

https://www.globenewswire.com/news-release/2024/09/05/2941064/0/en/NRG-Therapeutics-Awarded-Grant-Funding-from-Target-ALS-to-Support-the-Development-of-mPTP-Inhibitors-as-Novel-Treatments-for-ALS-MND.html

GLOBENEWSWIRE
05 Sep 2024

https://www.globenewswire.com/news-release/2023/04/26/2654702/0/en/NRG-Therapeutics-Appoints-Dr-Jonathan-Savidge-as-Independent-Chair.html

GLOBENEWSWIRE
26 Apr 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty